Additionally, the LSD1-deficient melanoma cells had increased sensitivity to anti-PD-1 therapy [68], suggesting that epigenetic targets that promote ICD marker expression may be utilized to promote tumor immunogenicity and to improve responsiveness to CI therapy. The gene discussed is PDCD1; the disease is neoplasm.